A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (PULMO-01)
A Phase I/IIa Study of Roginolisib in Combination With Dostarlimab With or Without Docetaxel in Patients With Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)
Sponsor: iOnctura
This PHASE1/PHASE2 trial investigates Advanced Non Squamous NSCLC and Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and is currently ongoing. iOnctura leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- iOnctura
For direct contact, visit the study record on ClinicalTrials.gov .